Sustained release formulations
AssigneeAmgen Inc.
InventorsMerrill S. Goldenberg, Jian Hua Gu
Life of this patent
Estimating the term…
Abstract
The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic acid ester is PentaGalloylGlucose (PGG) and in anther example the gallic acid ester is epigallocatechin gallate (EGCG).
Claims21
A pharmaceutical formulation comprising:
- a sustained release complex of a peptide of 20 amino acids or less, wherein said peptide is a B1 antagonist, and a purified gallic acid ester;
- and a pharmaceutically acceptable carrier or excipient, or both.
A method of making a pharmaceutical formulation comprising combining a peptide of 20 amino acids or less with epigallocatechin gallate (EGCG) under conditions such that a complex of the peptide and EGCG forms at a pH from 6.0 to 9.0, and preparing a pharmaceutical formulation comprising the complex.
A pharmaceutical formulation, comprising:
- a sustained release complex of a peptide of 20 amino acids or less, wherein said peptide is a B1 antagonist, and a purified gallic acid ester selected from PentaGalloylGlucose (PGG) and epigallocatechin gallate (EGCG);
- and
- a pharmaceutically acceptable carrier suitable for subcutaneous administration.
Dependencies are inferred from the claim text.